MedPath

Tagged News

€13.6M EU-Funded PREDI-LYNCH Project Aims to Transform Cancer Screening for Lynch Syndrome Patients

AIOncology
  • The PREDI-LYNCH project has received €13.6 million in EU funding to develop non-invasive liquid biopsy tests for early cancer detection in Lynch Syndrome carriers, addressing a critical unmet medical need.
  • Swedish diagnostics company Elypta joins 27 partners across 16 European countries in this six-year initiative (2025-2031), contributing its proprietary glycosaminoglycan-based biomarker technology.
  • With only 5% of Europe's estimated 2 million Lynch Syndrome carriers under cancer surveillance, the project aims to create affordable, accessible screening methods for colorectal, endometrial, and urothelial cancers.

IMVARIA Presents Real-World Data on FDA-Authorized AI Diagnostic Service for Pulmonary Fibrosis at ATS 2025

AI
  • IMVARIA's Fibresolve, the first FDA-authorized AI adjunctive diagnostic service for lung fibrosis, demonstrates real-world clinical utility in multi-site experiences presented at ATS 2025 Conference.
  • The AI-powered diagnostic service enables pulmonologists to evaluate suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF) without workflow disruption or complex system installation.
  • IMVARIA is also presenting data on two additional AI solutions: ScreenDx for ILD assessment (FDA-cleared in 2025) and Bronchosolve, an investigational tool for lung nodule evaluation.

Kakao Healthcare Expands AI-Powered Glucose Monitoring App to Japanese Market

AI
  • Kakao Healthcare Corp. is launching its AI-powered continuous glucose monitoring app PASTA in Japan through a new subsidiary, marking a significant step in the company's global expansion strategy.
  • PASTA integrates with CGM sensors from I-sens Inc.'s Caresens Air and Dexcom Inc.'s G7 system, providing advanced diabetes management capabilities through artificial intelligence technology.
  • The expansion follows Kakao's recent initiatives in data-driven healthcare, including plans to develop an "AI-platform bridge" connecting medical institutions, government, and industry for drug discovery and research.

AI in Oncology: Transforming Community Practice from Patient Care to Revenue Cycles

AIOncologyPrecision Medicine
  • AI adoption in oncology practices is rapidly growing, with current utilization at 40-50% and projected to reach 70-80% in the next few years, enhancing both clinical decision support and practice operations.
  • AI technologies are improving patient care by facilitating education, reducing financial toxicity, streamlining practice connections, and helping clinicians manage the increasing complexity of precision medicine data.
  • Community oncology practices need a pragmatic, strategic approach to AI implementation that prioritizes specific practice needs, workflow integration, and patient readiness to maximize benefits while addressing potential disparities.

Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration

AI
  • New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.
  • The validation studies utilized data from Boehringer Ingelheim's landmark INBUILD clinical trial, demonstrating e-Lung's ability to predict disease progression and patient outcomes independent of traditional CT imaging markers.
  • Brainomix's AI-powered imaging solution enables earlier treatment decisions and better patient prioritization, potentially addressing the critical diagnostic delay that affects pulmonary fibrosis patients who often wait up to two years for diagnosis.

Rakovina Therapeutics Secures $4M Strategic Financing to Advance AI-Powered Cancer Drug Discovery Platform

AIDrug DiscoveryOncology
  • Rakovina Therapeutics announced a strategic $4 million financing round anchored by $3 million from strategic investors to support its AI-powered oncology drug discovery platform.
  • The company will implement a 10-for-1 share consolidation to enhance its capital structure and position for accelerated growth in U.S. capital markets.
  • The financing will support Rakovina's proprietary DNA Damage Response platform targeting treatment-resistant cancers with impaired DNA repair pathways.
  • The company aims to advance its pipeline of DNA-damage response inhibitors toward human clinical trials through pharmaceutical partnerships.

Colorectal Cancer Leads in Real-World Data Volume, But Oncology Trials Need Modernization

Real World EvidenceAIPrecision MedicineOncology
• Phesi's analysis of 167 million patient records reveals colorectal cancer has the largest volume of real-world data with nearly six million records, outpacing breast, lung, liver, and prostate cancers.
• Despite the wealth of available data, oncology clinical trials continue to suffer from inefficiencies, with trial design and execution failing to keep pace with advances in biomarker science and patient profiling.
• Experts urge a shift toward "precision oncology" using AI and clinical data science to optimize patient profiles, programs, protocols, and operations plans to accelerate drug development.

IMU Biosciences Partners with Curiox for UK's Largest Immune Profiling Initiative

AIPrecision Medicine
  • IMU Biosciences has adopted Curiox's Pluto Workstation to support large-scale immune phenotyping within the £21.9 million MANIFEST consortium, the UK's largest immune profiling initiative.
  • The Pluto automation platform will enhance sample preparation quality and reproducibility for AI-driven immune profiling analytics, addressing critical challenges in traditional manual workflows.
  • The MANIFEST consortium aims to identify predictive biomarkers for cancer immunotherapy response, resistance, and immune-related adverse events through collaboration between 15 academic institutions and 11 industry partners.

OneMeta and Invictus BPO Form Strategic Partnership to Revolutionize Multilingual Customer Service

AI
  • OneMeta Inc. has established a licensing agreement with Invictus BPO, integrating its VerbumAgentis and VerbumSDK technologies into Invictus's iKunnect platform to enable real-time communication in over 140 languages.
  • The partnership aims to transform customer service interactions across diverse markets, particularly benefiting sectors like healthcare, e-commerce, and finance where multilingual support is essential.
  • This collaboration strengthens OneMeta's position in AI-powered multilingual communication while enhancing Invictus's service capabilities, creating more efficient and inclusive customer experiences globally.

Arrive AI Debuts on Nasdaq with Autonomous Delivery Technology for Healthcare Applications

AI
  • Arrive AI secured a direct listing on Nasdaq following nearly $12 million in crowdfunding and $40 million in institutional funding, marking a significant milestone for autonomous delivery technology.
  • The company's patented Autonomous Last Mile platform features AI-powered smart mailboxes with advanced safety capabilities including climate control, explosive material detection, and UV sterilization systems.
  • Arrive AI is actively collaborating with healthcare industry leaders to leverage its secure delivery platform where efficiency, accuracy and security are paramount for medical deliveries.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.